UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 218

Sortiert nach

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

Pharmacological reviews, 2013-01, Vol.65 (1), p.171

2013

Link zum Volltext

Verfügbarkeit prüfen

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

PloS one, 2016-11, Vol.11 (11), p.e0167235-e0167235

2016

Link zum Volltext

Verfügbarkeit prüfen

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Movement disorders, 2013-02, Vol.28 (2), p.131-144

2013

Link zum Volltext

Verfügbarkeit prüfen

Nondopaminergic mechanisms in levodopa-induced dyskinesia

Movement disorders, 2005-08, Vol.20 (8), p.919-931

Brotchie, Jonathan M.

2005

Link zum Volltext

Verfügbarkeit prüfen

Levodopa-induced dyskinesias

Movement disorders, 2007-07, Vol.22 (10), p.1379-1389

2007

Link zum Volltext

Verfügbarkeit prüfen

Serotonin and Parkinson's disease: On movement, mood, and madness

Movement disorders, 2009-07, Vol.24 (9), p.1255-1266

2009

Link zum Volltext

Verfügbarkeit prüfen

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future

Progress in brain research, 2010, Vol.184, p.133

2010

Link zum Volltext

Verfügbarkeit prüfen

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease

Journal of neuroinflammation, 2023-03, Vol.20 (1), p.79-79, Article 79

2023

Link zum Volltext

Verfügbarkeit prüfen

Brain-to-gut trafficking of alpha-synuclein by CD11c + cells in a mouse model of Parkinson's disease

Nature communications, 2023-11, Vol.14 (1), p.7529-7529, Article 7529

2023

Link zum Volltext

Verfügbarkeit prüfen

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice

Journal of neuroinflammation, 2022-12, Vol.19 (1), p.319-319, Article 319

2022

Link zum Volltext

Verfügbarkeit prüfen

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l -DOPA induced dyskinesia in mouse models

Neurobiology of disease, 2014-11, Vol.71, p.334-344

2014

Link zum Volltext

Verfügbarkeit prüfen

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Acta neuropathologica communications, 2020-02, Vol.8 (1), p.17-16, Article 17

2020

Link zum Volltext

Verfügbarkeit prüfen

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

The Journal of pharmacology and experimental therapeutics, 2010-06, Vol.333 (3), p.865

2010

Link zum Volltext

Verfügbarkeit prüfen

Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

Nature reviews. Neuroscience, 2001-08, Vol.2 (8), p.577-588

2001

Link zum Volltext

Verfügbarkeit prüfen

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease

Cells (Basel, Switzerland), 2020-03, Vol.9 (4), p.841

2020

Link zum Volltext

Verfügbarkeit prüfen

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

Neurobiology of disease, 2017-10, Vol.106, p.133-146

2017

Link zum Volltext

Verfügbarkeit prüfen

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein

PloS one, 2011-03, Vol.6 (3), p.e17698-e17698

2011

Link zum Volltext

Verfügbarkeit prüfen

Animal models of α-synucleinopathy for Parkinson disease drug development

Nature reviews. Neuroscience, 2017-09, Vol.18 (9), p.515

2017

Link zum Volltext

Verfügbarkeit prüfen

Non-dopaminergic treatments in development for Parkinson's disease

Lancet neurology, 2008-10, Vol.7 (10), p.927-938

2008

Link zum Volltext

Verfügbarkeit prüfen

Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease

Scientific reports, 2022-02, Vol.12 (1), p.3180-3180, Article 3180

2022

Link zum Volltext

Verfügbarkeit prüfen

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

The Journal of pharmacology and experimental therapeutics, 2011-10, Vol.339 (1), p.2

2011

Link zum Volltext

Verfügbarkeit prüfen

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

Molecular neurodegeneration, 2010-10, Vol.5 (1), p.43-43

2010

Link zum Volltext

Verfügbarkeit prüfen

l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

Neuropharmacology, 2012-10, Vol.63 (5), p.829-836

2012

Link zum Volltext

Verfügbarkeit prüfen

role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

The FASEB journal, 2005-07, Vol.19 (9), p.1140-1142

2005

Link zum Volltext

Verfügbarkeit prüfen

Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

The Journal of neuroscience, 2001-09, Vol.21 (17), p.6853-6861

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 218

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(198)

Publikationsform

Artikel
(213)
Buchkapitel
(5)

Sprache

Englisch
(218)
Japanisch
(43)

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(136)
Animals
(133)
Neurosciences & Neurology
(110)
Parkinson's Disease
(91)
Neurosciences
(78)
Male
(67)
Disease Models, Animal
(59)
Humans
(58)
Biological And Medical Sciences
(56)
Female
(55)
Neurology
(54)
Medical Sciences
(51)
Dyskinesia
(47)
Rats
(45)
Clinical Neurology
(43)
Rats, Sprague-Dawley
(41)
Levodopa - Adverse Effects
(38)
Parkinson Disease - Drug Therapy
(36)
Antiparkinson Agents - Adverse Effects
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Nondopaminergic mechanisms in levodopa-induced dyskinesia

Levodopa-induced dyskinesias

Serotonin and Parkinson's disease: On movement, mood, and madness

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease

Brain-to-gut trafficking of alpha-synuclein by CD11c + cells in a mouse model of Parkinson's disease

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l -DOPA induced dyskinesia in mouse models

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein

Animal models of α-synucleinopathy for Parkinson disease drug development

Non-dopaminergic treatments in development for Parkinson's disease

Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

Suchergebnisse filtern